Last reviewed · How we verify

Paclitaxel (albumin-bound)

Dai, Guanghai · FDA-approved active Small molecule

Paclitaxel (albumin-bound) is a Taxane; microtubule stabilizer Small molecule drug developed by Dai, Guanghai. It is currently FDA-approved for Metastatic breast cancer, Non-small cell lung cancer, Pancreatic cancer. Also known as: carboplatin.

Paclitaxel binds to and stabilizes microtubules, preventing their disassembly and causing cell cycle arrest and apoptosis in cancer cells.

Paclitaxel binds to and stabilizes microtubules, preventing their disassembly and causing cell cycle arrest and apoptosis in cancer cells. Used for Metastatic breast cancer, Non-small cell lung cancer, Pancreatic cancer.

At a glance

Generic namePaclitaxel (albumin-bound)
Also known ascarboplatin
SponsorDai, Guanghai
Drug classTaxane; microtubule stabilizer
Targetβ-tubulin (microtubule)
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Paclitaxel is a taxane that binds to β-tubulin within microtubules, stabilizing them and preventing depolymerization. This disrupts the dynamic reorganization of the microtubule cytoskeleton required for cell division, leading to mitotic arrest in the G2/M phase and subsequent apoptosis. The albumin-bound formulation (nab-paclitaxel) uses human serum albumin as a carrier to improve solubility and reduce hypersensitivity reactions compared to conventional paclitaxel.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Paclitaxel (albumin-bound)

What is Paclitaxel (albumin-bound)?

Paclitaxel (albumin-bound) is a Taxane; microtubule stabilizer drug developed by Dai, Guanghai, indicated for Metastatic breast cancer, Non-small cell lung cancer, Pancreatic cancer.

How does Paclitaxel (albumin-bound) work?

Paclitaxel binds to and stabilizes microtubules, preventing their disassembly and causing cell cycle arrest and apoptosis in cancer cells.

What is Paclitaxel (albumin-bound) used for?

Paclitaxel (albumin-bound) is indicated for Metastatic breast cancer, Non-small cell lung cancer, Pancreatic cancer, Ovarian cancer.

Who makes Paclitaxel (albumin-bound)?

Paclitaxel (albumin-bound) is developed and marketed by Dai, Guanghai (see full Dai, Guanghai pipeline at /company/dai-guanghai).

Is Paclitaxel (albumin-bound) also known as anything else?

Paclitaxel (albumin-bound) is also known as carboplatin.

What drug class is Paclitaxel (albumin-bound) in?

Paclitaxel (albumin-bound) belongs to the Taxane; microtubule stabilizer class. See all Taxane; microtubule stabilizer drugs at /class/taxane-microtubule-stabilizer.

What development phase is Paclitaxel (albumin-bound) in?

Paclitaxel (albumin-bound) is FDA-approved (marketed).

What are the side effects of Paclitaxel (albumin-bound)?

Common side effects of Paclitaxel (albumin-bound) include Peripheral neuropathy, Neutropenia, Anemia, Thrombocytopenia, Myalgia/arthralgia, Nausea/vomiting.

What does Paclitaxel (albumin-bound) target?

Paclitaxel (albumin-bound) targets β-tubulin (microtubule) and is a Taxane; microtubule stabilizer.

Related